Exploring China's frontier healthcare breakthroughs โ from innovative drugs and cell therapies to AI-assisted diagnostics and global-first medical technologies.
China's first AI-assisted original drug has been approved, and the first AI-discovered drug has entered Phase III trials. How artificial intelligence is compressing drug development timelines.
Chinese biopharma has evolved beyond simple out-licensing. Co-Co agreements with Pfizer, platform-level collaborations with BMS, and NewCo structures are reshaping global market access.
Over the past decade, China's innovative drug industry has undergone a quiet but profound transformation. In H1 2026 alone, 38 Class 1 innovative drugs were approved, while out-licensing deals approached $110 billion.
China now contributes nearly 40% of the world's ADC R&D pipeline. From the world's first approved bispecific ADC to next-generation dual-payload technologies, explore how China is leading the "biological missile" revolution in oncology.
Comprehensive guide to EGFR (osimertinib, almonertinib, furmonertinib, etc.), ALK, ROS1, MET, KRAS, HER2 targeted therapies in China. Over a dozen EGFR-TKIs now available, with fourth-generation candidates in the pipeline.
China's drug approval system has been transformed from a 30-month bottleneck to a 30-day catalyst for innovation. Explore the four accelerated pathways, IND silent approval, and the reform timeline that made it possible.
China's first AI-assisted original drug has been approved, and the first AI-discovered drug has entered Phase III trials. How artificial intelligence is compressing drug development timelines.
First-in-human RNA editing for Duchenne muscular dystrophy, fully automated chemical reprogramming of stem cells, and iPSC-derived cell therapy for Parkinson's disease.
NEO โ the world's first commercially approved implantable BCI, with first-in-human commercial implant surgery performed at Huashan Hospital.
Sub-micron precision microsurgery robots, force feedback laparoscopic systems, and remote surgery across 4,000 kilometers.
Fully magnetically levitated artificial heart, world's first non-invasive cardiac radiotherapy system, and domestically produced ECMO.
China's first domestically produced BNCT system โ HyBorSysยฎ โ has completed registration inspection and entered clinical trials for glioblastoma and head and neck cancer.
100-billion-parameter foundation models, AI-assisted pulmonary nodule differentiation, and AI pediatricians serving 150+ county-level hospitals.
Portable head MRI systems bring brain imaging to the bedside โ enabling rapid stroke assessment and neurological diagnosis in emergency and intensive care settings.
Asia's first robotic hair transplant system with sub-millimeter precision, automated graft extraction, and AI-assisted hairline design.
A new generation of cardiac sealant devices dissolves naturally in the body, closing congenital heart defects without leaving a permanent implant.
China's first domestically developed trifocal toric IOL addresses cataract, presbyopia, and astigmatism simultaneously โ a breakthrough in refractive cataract surgery.
Comprehensive overview of China's CAR-T cell therapy landscape: approved products, pipeline, manufacturing innovations, global out-licensing, and future directions.
More articles coming soon. Stay tuned for updates on gene therapy, advanced diagnostics, and other frontier technologies.
While China's oncology innovation attracts global attention, equally significant breakthroughs are occurring in rare disease gene therapy, Alzheimer's disease, and oligonucleotide therapeutics.
The first phase 3 trial demonstrating that the China-developed ADC sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly outperforms pembrolizumab alone in first-line PD-L1โpositive advanced NSCLC without targetable alterations. Interim analysis shows median PFS not reached vs 5.7 months (HR 0.35, p<0.0001).
The world's first approved CAR-T therapy for solid tumors โ Shurui Jiao'ao (Shuruiยฎ) for CLDN18.2-positive gastric cancer. A historic milestone in cancer immunotherapy.
China-developed LEAPER RNA editing technology achieves the world's first clinical application in DMD, with 3 patients showing sustained motor function improvement and no serious adverse events at 1-year follow-up. Published in Cell.
China's first siRNA therapy for SOD1-associated ALS demonstrates 56โ69% CSF SOD1 reduction and 52โ62% neurofilament light chain reduction with no serious adverse events in first-in-human trial.
Single-dose AAV gene therapy (NGGT006) achieves sustained LDL-C reduction from 11 mmol/L to below 1.8 mmol/L in HoFH patients, with no vector-related serious adverse events.
The world's largest randomized controlled trial of iPSC-derived cardiomyocyte therapy for severe heart failure demonstrates improved cardiac function and quality of life with no tumorigenicity.
First-in-human iPSC-derived neural progenitor cell therapy for hemorrhagic stroke demonstrates durable functional recovery with 2.5-year follow-up and has obtained FDA IND approval.
QT-019C, a dual-targeting allogeneic CAR-T from Qihan Biotech, is the first Chinese cell therapy to receive FDA RMAT and Breakthrough Therapy Designation for autoimmune disease (SLE and myasthenia gravis).
XLRS gene therapy โ the first Chinese ophthalmic gene therapy to be published in the New England Journal of Medicine โ demonstrates safety and durable visual improvement in X-linked retinoschisis patients.
China's first domestically developed gene therapy for inherited retinal dystrophy (IRD) has successfully completed a Phase III clinical trial, marking a milestone for Chinese ophthalmic gene therapy.
A human iPSC-derived retinal progenitor cell therapy for retinitis pigmentosa receives both NMPA IND approval in China and FDA IND clearance โ the first cell therapy for RP with dual regulatory authorization.
A fully human ANGPTL3 monoclonal antibody demonstrates 64.2% LDL-C reduction in HoFH patients in a Phase III study presented as a Late-Breaking Abstract at ESC 2026.
An oral small-molecule Lp(a) inhibitor demonstrates dose-dependent Lp(a) reduction of up to 86.3% in Phase II study presented as a Late-Breaking Abstract at ESC 2026.
China's first 128-channel fully implantable BCI system initiates a multi-center clinical trial at Beijing Tiantan Hospital, enrolling 32 patients with severe motor impairment.
GA002, a 1-class innovative drug, initiates a Phase I/II clinical trial for drug-resistant epilepsy, employing a precision gene-editing approach to silence abnormal neuronal discharges.
More articles coming soon. Stay tuned for updates on global-first drug approvals, surgical innovations, and medical device breakthroughs.
China's 2026 medical insurance negotiation introduced the first-ever dual-track system, bringing million-yuan CAR-T therapies to the negotiating table and establishing an 8-year price protection mechanism.
Chinese biopharma has evolved beyond simple out-licensing. Co-Co agreements with Pfizer, platform-level collaborations with BMS, and NewCo structures are reshaping global market access.
In 2026, Chinese innovative drugs achieved historic FDA approvals: Cypsedoยฎ (anesthetic) and Langlaraยฎ (insulin). A milestone for China's biopharma globalization.
China's innovative drug out-licensing deals reached $110 billion in H1 2026. 81 deals, 8 of the global Top 10 from Chinese sellers. A historic boom in global biopharma licensing.
Chinese innovative drugs are now being included in international clinical guidelines: APASL, CSCO, and beyond. A new era of global recognition for Chinese biopharma.
In 2026, Chinese biotech companies initiated 6 global Phase III clinical trials as sole sponsors with U.S. sites โ a historic milestone in global drug development.
Chinese vaccines are gaining WHO prequalification: WALRINVAXยฎ (HPV), and the first Chinese 9-valent HPV vaccine submitted for WHO PQ. China's vaccines go global.